FDA gives green light to ANDA for chewable diabetes tablet

Article

FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.

Recent Videos
Image Credit: anidimi - stock.adobe.com
Image Credit: เลิศลักษณ์ ทิพชัย - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.